Claret Capital Partners participates in €130m financing for Inventiva Inventiva is a clinical biopharmaceutical company developing an oral treatment for chronic liver disease, MASH Claret Capital Partners is providing growth funding of €43m as part of Inventiva's €130m debt financing Latest in a series of late stage, European biotech investments by Claret Capital as part of its expansion in life sciences London, 16 June, 2026, Claret Capital Partners ('Claret'), Europe's largest independent growth debt fund manager has made an investment through its funds, of €43m in Inventiva (Euronext Paris and NASDAQ: IVA), a clinical-stage biopharmaceutical company developing an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), a common and progressive chronic liver disease.
